Phase 3 Lymphoma Trial, Recruiting NCT06929624 Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT06929624
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed through a tissue test to have a type of cancer called diffuse large B-cell lymphoma (DLBCL)
  • People who have already received at least one round of treatment for their cancer
  • People who have at least one measurable area of cancer that can be tracked in two directions (confirm with trial site)
  • People whose doctors expect them to live for at least 3 months
  • People who are 18 years of age or older but under 80 years of age
  • People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments

Who may not be able to join:

  • People whose lymphoma has spread to the central nervous system (the brain or spinal cord)
  • People whose lymphoma started in the area behind the breastbone (the mediastinum/thymus region)
  • People who have only had one prior treatment and whose doctors consider them suitable candidates for a stem cell transplant
  • People who have a history of immune system deficiency
  • People who have a history of serious heart or cardiovascular disease
  • People who have been diagnosed with another type of cancer within the last 5 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Registry
ClinicalTrials.gov
Start date
24 April 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate (CRR); Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov